



February 20, 2012

Biocept to present at Molecular Tri-Conference on Circulating Tumor Cells (CTCs)

San Diego, California – Biocept, Inc., a privately-held, CLIA certified laboratory testing company focused on detection and analysis of circulating tumor cells (CTCs) in cancer patients, announced that two of its senior scientists, Farideh Bischoff, Ph.D., Vice President of Translational Research, and Lyle Arnold, Ph.D., Senior Vice President, R&D and Chief Scientific Officer, will be making presentations at the 19th Annual Molecular Medicine Tri-Con being held in San Francisco February 19-23.

Dr. Arnold will speak during the “Blood-Based Cancer Diagnostics” session on Monday, February 20th. His talk, entitled “The Capture, Identification and Interrogation of Circulating Tumor Cells”, will touch on a proprietary, highly sensitive mutation detection technology developed at Biocept called “Selector™”. Dr. Bischoff will speak during the “Clinical Use of Circulating Tumor Cells” session on Wednesday, February 22nd. Her talk, entitled “Capture and Detection of CK+ and CK- CTCs for Subsequent Molecular Analysis Using the OncoCEETM Platform”, will cover in part a continuing clinical study in breast cancer with collaborators at the MD Anderson Cancer Center.

Biocept’s first test, OncoCEE-BRTM for breast cancer, is available through its commercialization partner Clariant, Inc., a GE Healthcare Company. The test includes CTC enumeration and determination of HER2 status by fluorescence in situ hybridization (FISH) from a blood sample. Determination of estrogen receptor (ER) and progesterone receptor (PR) status by immunocytochemical staining will be added to the test later this year. OncoCEE-BR is the first commercially available CTC test to include analysis of a specific, treatment-associated biomarker (HER2).